Taiwan's Formosa Pharmaceuticals signs an exclusive licensing agreement with Tabuk for clobetasol propionate ophthalmic suspension in the MENA region.
Taiwan's Formosa Pharmaceuticals signs an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company to commercialize clobetasol propionate ophthalmic suspension, a patented treatment for inflammation and pain after ocular surgery, in the MENA region. The agreement includes upfront, commercialization, and sales milestones, leveraging Formosa's proprietary APNT™ nanoparticle formulation platform for a convenient dosing regimen.
May 09, 2024
3 Articles